Price | 1W % | 1M % | 3M % | 6M % | 1Y % | YTD % |
---|---|---|---|---|---|---|
-- | -- | -- | -- | -- | -- | -- |
AI Generated Qualitative Analysis
Your time is precious, so save it. Use AI to get the most important information from the business.
Learn about Abbott Laboratories
Abbott Laboratories News
Abbott Laboratories Quantitative Score
About Abbott Laboratories
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.
Abbott Laboratories Earnings & Revenue
Abbott Laboratories Financials
Table Compare
Compare ABT metrics with: | |||
---|---|---|---|
Earnings & Growth | ABT | None | |
EPS (TTM) YoY Growth | -- | -- | |
Revenue (TTM) YoY Growth | -- | -- | |
Valuation (TTM) | ABT | None | |
Price/Earnings Ratio | -- | -- | |
Price/Sales Ratio | -- | -- | |
Profitability & Efficiency (TTM) | ABT | None | |
Net Profit Margin | -- | -- | |
Return on Equity | -- | -- | |
Financial Health (TTM) | ABT | None | |
Debt/Assets Ratio | -- | -- | |
Assets/Liabilities Ratio | -- | -- | |
Abbott Laboratories Income
Abbott Laboratories Balance Sheet
Abbott Laboratories Cash Flow
Abbott Laboratories Financials Over Time
Analysts Rating
Strong Buy
Buy
Hold
Sell
Strong Sell
Metrics Scores
Metrics | Score |
---|---|
Discounted Cash Flows | Buy |
Return on Equity | Buy |
Return on Assets | Strong Buy |
Debt/Equity Ratio | Sell |
Price/Earnings Ratio | Strong Sell |
Price/Book Ratio | Strong Sell |
Price Targets
Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.
Abbott Laboratories Dividends
Yield (TTM) | Dividend (TTM) | |
---|---|---|
Infinity% | 2.2000 |
Payment Date | Dividend | Frequency |
---|---|---|
2024-11-15 | 0.55 | Quarterly |
2024-08-15 | 0.55 | Quarterly |
2024-05-15 | 0.55 | Quarterly |
2024-02-15 | 0.55 | Quarterly |
2023-11-15 | 0.51 | Quarterly |
Abbott Laboratories Valuation
Project future cash flows and get the intrinsic value per share.
Historical Market Cap
Shares Outstanding
Abbott Laboratories Executives
Name | Role |
---|---|
Mr. Robert B. Ford | Chairman of the Board, President & Chief Executive Officer |
Mr. Hubert L. Allen J.D. | Executive Vice President, General Counsel & Secretary |
Mr. Daniel Gesua Sive Salvadori | Executive Vice President and Group President of Established Pharmaceuticals & Nutritional Products |
Ms. Lisa D. Earnhardt | Executive Vice President & Group President of Medical Devices |
Mr. Philip P. Boudreau | Chief Financial Officer & Executive Vice President of Finance |
Name | Role | Gender | Date of Birth | Pay |
---|---|---|---|---|
Mr. Robert B. Ford | Chairman of the Board, President & Chief Executive Officer | Male | 1974 | 4.73M |
Mr. Hubert L. Allen J.D. | Executive Vice President, General Counsel & Secretary | Male | 1966 | 2M |
Mr. Daniel Gesua Sive Salvadori | Executive Vice President and Group President of Established Pharmaceuticals & Nutritional Products | Male | 1979 | 1.76M |
Ms. Lisa D. Earnhardt | Executive Vice President & Group President of Medical Devices | Female | 1970 | 1.73M |
Mr. Philip P. Boudreau | Chief Financial Officer & Executive Vice President of Finance | Male | 1973 | 1.14M |
Abbott Laboratories Insider Trades
Date | 21 Oct |
Name | ALLEN HUBERT L |
Role | EXECUTIVE VICE PRESIDENT |
Transaction | Acquired |
Type | M-Exempt |
Shares | 157421 |
Date | 21 Oct |
Name | ALLEN HUBERT L |
Role | EXECUTIVE VICE PRESIDENT |
Transaction | Disposed |
Type | S-Sale |
Shares | 1249 |
Date | 21 Oct |
Name | ALLEN HUBERT L |
Role | EXECUTIVE VICE PRESIDENT |
Transaction | Disposed |
Type | S-Sale |
Shares | 5901 |
Date | 21 Oct |
Name | ALLEN HUBERT L |
Role | EXECUTIVE VICE PRESIDENT |
Transaction | Disposed |
Type | S-Sale |
Shares | 150271 |
Date | 21 Oct |
Name | ALLEN HUBERT L |
Role | EXECUTIVE VICE PRESIDENT |
Transaction | Disposed |
Type | M-Exempt |
Shares | 157421 |
Date | Name | Role | Transaction | Type | Shares |
---|---|---|---|---|---|
21 Oct | ALLEN HUBERT L | EXECUTIVE VICE PRESIDENT | Acquired | M-Exempt | 157421 |
21 Oct | ALLEN HUBERT L | EXECUTIVE VICE PRESIDENT | Disposed | S-Sale | 1249 |
21 Oct | ALLEN HUBERT L | EXECUTIVE VICE PRESIDENT | Disposed | S-Sale | 5901 |
21 Oct | ALLEN HUBERT L | EXECUTIVE VICE PRESIDENT | Disposed | S-Sale | 150271 |
21 Oct | ALLEN HUBERT L | EXECUTIVE VICE PRESIDENT | Disposed | M-Exempt | 157421 |